How did BSX's revenue and expenses trend in Q4 2024?

Boston Scientific Corporation (BSX) experienced a notable increase in revenue and a slight rise in net income in Q4 2024, despite higher operating and gross expenses compared to the same period the previous year. 1. **Revenue Growth**: BSX's revenue for Q4 2024 was $4.34-$4.41 billion, compared to the consensus revenue estimate of $4.28 billion. This represents a significant upward from the $3.54 billion reported in Q4 2023. The reported growth is a result of strong performance across key segments and regions. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |BSX|BSX.N|Boston Scientific|20240101-2024|Cardiovascular|1.0755E10|169| |BSX|BSX.N|Boston Scientific|20240101-2024|Cardiovascular|7.813E9|169| |BSX|BSX.N|Boston Scientific|20240101-2024|Cardiovascular|5.082E9|169| |BSX|BSX.N|Boston Scientific|20240101-2024|Cardiovascular|2.445E9|169| |BSX|BSX.N|Boston Scientific|20240101-2024|Cardiovascular|2.445E9|169| |BSX|BSX.N|Boston Scientific|20240101-2024|Medsurg|1.412E9|169| |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |BSX|BSX.N|Boston Scientific|2024 Q1|57.00636942675159|4.93E8|169| |BSX|BSX.N|Boston Scientific|2024 Q2|19.25925925925926|3.22E8|169| |BSX|BSX.N|Boston Scientific|2024 Q3|-7.142857142857142|4.68E8|169| |BSX|BSX.N|Boston Scientific|2024 Q4|11.507936507936508|5.62E8|169| |code|Ticker|Name|Date|Gross PP&E YoY|Gross PP&E|market_code| |---|---|---|---|---|---|---| |BSX|BSX.N|Boston Scientific|20240331|10.10793215692993|6.427E9|169| |BSX|BSX.N|Boston Scientific|20240630|9.22509225092251|6.512E9|169| |BSX|BSX.N|Boston Scientific|20240930|10.062479447550148|6.694E9|169| |BSX|BSX.N|Boston Scientific|20241231|7.630458773451049|6.827E9|169| 2. **Net Income and Profit Margin**: The company reported a GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago. This decrease in net income margin was primarily driven by higher operating and gross expenses. 3. **Operating and Gross Expenses**: The specifics of the operating and gross expenses for Q4 2024 are not available. However, it is clear that the increase in expenses contributed to the decrease in net margin. The company's focus on innovation and market expansion, as evidenced by its product pipeline and clinical evidence, is likely reflected in the higher expense levels. 4. **Segmental Performance**: BSX's MedSurg segment experienced a 10.3% increase in revenue, while the Cardiovascular segment saw a significant boost, with a 25.0% reported growth. These segmental performances underscore the company's strategic focus and market leadership in high-growth areas. In conclusion, while BSX faced increased expenses in Q4 2024, its revenue growth, particularly in key segments, and operational execution have resulted in solid net income and earnings per share. The company's guidance for FY 2024 suggests a positive outlook, with expected EPS growth aligning with market expectations.